Tag Archives: Novartis

Novartis’ Sandoz goes digital from back office to ‘not just apps,’ therapeutics

how-digital-is-reshaping-the-pharma-arenaPharma’s digital revolution is well underway, and Sandoz is placing some big bets that tech can transform the company—and everything it does.

    The Novartis generics business is taking on digital and data technologies from discovery and development all the way to commercialization, believing the approach can open up healthcare access and improve patient outcomes.

Leading the digital transformation push in North America is Carol Lynch, president of Sandoz U.S. and head of North America, and Mike Fraser, VP of strategy, innovation and analytics.

The two talked to FiercePharma recently about Sandoz and Novartis’ strategy, programs and mission in digital technology.

Click here for more…

Novartis to buy France’s Advanced Accelerator for $3.9 bln

NovartisZURICH, Oct 30 (Reuters) – Swiss drugmaker Novartis on Monday said it was buying France’s Advanced Accelerator Applications (AAA) in a $3.9 billion cash deal to strengthen the oncology portfolio at the world’s biggest maker of prescription medicines.

Basel-based Novartis is offering $41 per ordinary share and $82 per American depositary share for AAA, which makes radiopharmaceuticals including the product Lutathera that are used for both diagnosis and therapy. (Reporting by John Miller; Editing by Michael Shields)